Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial.

ABSTRACT:

Importance

Impairment of dopaminergic transmission may contribute to cognitive dysfunction in Alzheimer disease (AD).

Objective

To investigate whether therapy with dopaminergic agonists may affect cognitive functions in patients with AD.

Design, setting, and participants

This phase 2, monocentric, randomized, double-blind, placebo-controlled trial was conducted in Italy. Patients with mild to moderate AD were enrolled between September 1, 2017, and December 31, 2018. Data were analyzed from July 1 to September 1, 2019.

Interventions

A rotigotine 2 mg transdermal patch for 1 week followed by a 4 mg patch for 23 weeks (n = 47) or a placebo transdermal patch for 24 weeks (n = 47).

Main outcomes and measures

The primary end point was change from baseline on

SUBMITTER: Koch G 

PROVIDER: S-EPMC7364345 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature